PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 105 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $201,000 | +16.2% | 40,198 | +64.3% | 0.00% | – |
Q1 2021 | $173,000 | -78.1% | 24,460 | -80.6% | 0.00% | -100.0% |
Q4 2020 | $790,000 | -0.8% | 126,208 | -21.0% | 0.00% | 0.0% |
Q3 2020 | $796,000 | +325.7% | 159,762 | +345.0% | 0.00% | – |
Q2 2020 | $187,000 | +61.2% | 35,898 | -2.8% | 0.00% | – |
Q1 2020 | $116,000 | -38.0% | 36,948 | -20.3% | 0.00% | – |
Q4 2019 | $187,000 | -25.8% | 46,348 | -20.5% | 0.00% | – |
Q3 2019 | $252,000 | -25.0% | 58,323 | -30.7% | 0.00% | – |
Q2 2019 | $336,000 | -30.3% | 84,123 | -6.4% | 0.00% | -100.0% |
Q1 2019 | $482,000 | -4.6% | 89,865 | -8.8% | 0.00% | 0.0% |
Q4 2018 | $505,000 | -47.2% | 98,528 | -0.1% | 0.00% | 0.0% |
Q3 2018 | $957,000 | +6.0% | 98,675 | +11.4% | 0.00% | -50.0% |
Q2 2018 | $903,000 | -21.5% | 88,573 | +0.1% | 0.00% | 0.0% |
Q1 2018 | $1,150,000 | +166.2% | 88,494 | +266.3% | 0.00% | +100.0% |
Q4 2017 | $432,000 | +49.5% | 24,157 | +109.6% | 0.00% | 0.0% |
Q3 2017 | $289,000 | – | 11,525 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |